Objective
To integrate in vitro tests or models, based on human liver-derived systems. for predicting the metabolism and metabolic interactions of drugs and chemicals which are likely to occur following their exposure in man and compare these with results in vivo.
Detailed knowledge of the metabolism of pharmaceuticals is essential as early as possible in the research and development process, for two main reasons. The metabolism of drugs is generally the major determinant of their pharmacokinetic behaviour, interindividual variability and interactions with other compounds, all factors that complicate drug treatment. Differences in metabolism are also very often responsible for difficulties in extrapolating from a toxicology test species to humans, which can be a serious obstacle in drug testing and development.
A large number of approaches, based largely, but not solely on human-derived systems, for the prediction of drug metabolism are under development, although not all areas are as well advanced as some. The project will involve the selection or development of suitable model substances and reagents which will be used to define rigorously the various candidate in vitro methods and approaches, the application of the most promising methods and approaches to existing drugs and substances under development, i.e. "real" compounds from the participating industrial laboratories, and a comparison of the predictive power of these approaches to metabolism in vivo, determined in volunteers. The likely outcome is the identification of suitable tests, and the development of an integrated approach to the prediction of the metabolism of drugs. This could be used in drug discovery, in the design and execution of toxicity tests and of early clinical trials.
Other major tangible benefits will accrue, such as a decrease in the cost of drug development and acceleration of the process, because clinical studies could be targeted on the basis of in vitro results. The project will help to reduce the number of animals required currently in the preclinical development of pharmaceuticals.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs
- medical and health sciences basic medicine toxicology
You need to log in or register to use this function
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Data not available
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
90220 OULU
Finland
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.